ReviewOncoTargets and therapy2017
Carcinogenicity of chromium and chemoprevention: a brief update.
Review in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 261 citations in OpenAlex.
- Visible-light-driven photocatalytic reduction of Cr(VI) over EDTA-TiOScientific reports · 2026Article
- Hexavalent Chromium and Hexavalent Uranium Induce Mitochondrial Damage and Transcriptomic Alterations in Chinese Soft-Shelled Turtle Embryo Fibroblasts.Biological trace element research · 2026Article
- Carbon-supported metal catalysts for the capture/degradation of toxic gases.Scientific reports · 2026Article
- Development and Verification of a Suspension-Based TXRF Method for Chromium Determination in Feed and Fecal Samples Containing Chromic Oxide as an External Digestibility Marker.Molecules (Basel, Switzerland) · 2026Article
- Mechanism of Liver Injury Induced by CrAnimals : an open access journal from MDPI · 2026Article
- Article
- Elemental Composition of Women's Fingernails: A Comparative Analysis Between Cervical Cancer Patients and Healthy Individuals.Biological trace element research · 2025Article
- An Overview of Hexavalent Chromium-Induced Necroptosis, Pyroptosis, and Ferroptosis.Biological trace element research · 2025Review
- Highly Dense TiOMicromachines · 2025Article
- Characterization and Molecular Insights of a Chromium-Reducing BacteriumMicroorganisms · 2024Article
- Nuclear factor erythroid 2-related factor 2 (Nrf2) signaling in heavy metals-induced oxidative stress.Heliyon · 2024Review
- Metals on the Menu-Analyzing the Presence, Importance, and Consequences.Foods (Basel, Switzerland) · 2024Review
- Selective Isolation and Identification of Microorganisms with Dual Capabilities: Leather Biodegradation and Heavy Metal Resistance for Industrial Applications.Microorganisms · 2024Article
- Article
- A Systematic Review on Heavy Metals Contamination in Bangladeshi Fruits and Their Associated Health Risks.Environmental health insights · 2024Review
- Prosthetic Metals: Release, Metabolism and Toxicity.International journal of nanomedicine · 2024Review
- Metal toxin threat in wildland fires determined by geology and fire severity.Nature communications · 2023Article
- Removal of CrScientific reports · 2023Article
- A regional approach for health risk assessment of toxicants in plastic food containers.Toxicological research · 2023Review
- Exploration of Whole Blood Chromium as Biomarker of Hexavalent Chromium Exposure: Based on Literature Review and Monte Carlo Simulation.Biological trace element research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromium has two main valence states: hexavalent chromium (Cr[VI]) and trivalent chromium (Cr[III]). Cr(VI), a well-established human carcinogen, can enter cells by way of a sulfate/phosphate anion-transport system, and then be reduced to lower-valence intermediates consisting of pentavalent chromium (Cr[V]), tetravalent chromium (Cr[IV]) or Cr(III) via cellular reductants. These intermediates may directly or indirectly result in DNA damage or DNA-protein cross-links. Although Cr(III) complexes cannot pass easily through cell membranes, they have the ability to accumulate around cells to induce cell-surface morphological alteration and result in cell-membrane lipid injuries via disruption of cellular functions and integrity, and finally to cause DNA damage. In recent years, more research, including in vitro, in vivo, and epidemiological studies, has been conducted to evaluate the genotoxicity/carcinogenicity induced by Cr(VI) and/or Cr(III) compounds. At the same time, various therapeutic agents, especially antioxidants, have been explored through in vitro and in vivo studies for preventing chromium-induced genotoxicity/carcinogenesis. This review aims to provide a brief update on the carcinogenicity of Cr(VI) and Cr(III) and chemoprevention with different antioxidants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.